May 2, 2025
| Today’s news and insights for biopharma leaders
Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in revenue for Amgen's biosimilar business.
|
News roundup
The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it expand use of a top drug.
|
Tracker
A new HHS policy could add cost and time to the development of new vaccines, while NIH is putting its support behind an effort to develop universal flu and coronavirus shots.
|
Patent protection will run out later this decade for many multibillion-dollar medicines and will force their large pharmaceutical makers to find new products and markets. Learn more in
|
Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.
|
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.
|
|
Amidst an industry-wide shift to digital solutions, GenAI is helping biopharma leaders create a frictionless contact center and deliver personalized experiences. Learn more in this playbook.
|
|
From Our Library
Playbook
Custom content for MRN
|
Infographic
Custom content for UBC
|
Trendline
Supported by Quest Diagnostics
|
| 
